Transitioning Between Biologics
Main Article Content
Keywords
Psoriasis, Biologics, Switching, Changing, Transitioning
Abstract
Background: Transitioning between biologics has become an important part of practice.
Objective: Patients with moderate to severe plaque psoriasis who are on biologics can have efficacy failures, as well as safety concerns. This would often necessitate a change of biologic, which may be within the same class or to a different class. A change due to an adverse event from the presently used biologic may resolve or require treatment until a new biologic is introduced, which may pose some delay in the initiation of the subsequent biologic.
Methods: A review of the literature and guidelines published were performed.
Results: A practical guide to transitioning between biologics are presented
Limitations: There are no randomized placebo-controlled trials to determine the best method of transitioning between biologics.
Conclusion: Transitioning between biologics is an option for those patients requiring such a change either for safety or efficacy reasons.
References
2. Gladman D, Poulin Y, Adams K, et.al. Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice The Journal of Rheumatology Apr 2017, 44 (4) 519-534
3. Piaserico, Stefano et al. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry Journal of the American Academy of Dermatology , 2014 Volume 70 Issue 2 , 257 - 262.e3
4. Mrowietz, U. , Steinz, K. and Gerdes, S., Psoriasis: to treat or to manage?.2014 Exp Dermatol, 23: 705-709. doi:10.1111/exd.12437
5. Gulliver, W., Lynde, C., Dutz, J. et al.. Think beyond the Skin: 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis. Journal of Cutaneous Medicine and Surgery, 2015 19(1), 22–27. https://doi.org/10.2310/7750.2014.13151
6. Mrowietz, U. , de Jong, E. , Kragballe, K. , et al., A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis. 2014 J Eur Acad Dermatol Venereol, 28: 438-453.
7. Smith, C. , Jabbar‐Lopez, Z. , Yiu, Z. , et. al British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol, 177: 628-636.
8. Dunbar-Jacob, J. et al., Treatment adherence in chronic disease Journal of Clinical Epidemiology , Volume 54 , Issue 12 , S57 - S60
9. Ahluwalia, V., Rampakakis, E., Movahedi, M. et al. Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiative Clin Rheumatol (2017) 36: 2421. https://doi.org/10.1007/s10067-017-3805-4
10. Cather JC, Crowley JJ. Use of biologic agents in combination with other therapies for the treatment of psoriasis. Am J Clin Dermatol. 2014;15(6):467-78.
11. Choi, Young M. et al. From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology ,2016 Volume 75 , Issue 4 , 798 - 805.e7
12. Mrowietz U, Kragballe K, Reich , et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus J Eur Acad Dermatol Venereol 2011; 25 Suppl 3: 1–13.
13. Downs, A. (2010), Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor α biologics and switched to ustekinumab. British Journal of Dermatology, 163: 433-434.
14. Puig et.al. Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment Actas Dermo-Sifiliográficas (English Edition) Volume 104, Issue 8, October 2013, Pages 694-709
15. Menter A, Strober B, Kaplan D et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology , 2019 Volume 80 , Issue 4 , 1029 - 1072
16. National Institute for Health and Care Excellence, NICE Guidelines, Oct 2012-Updated Dec 2017- Sec 1.5.3.4 Psoriasis: assessment and management
17. Leman, J. and Burden, A, Sequential use of biologics in the treatment of moderate‐to‐severe plaque psoriasis. British Journal of Dermatology,2012, 167: (Suppl 3)12-20.
18. Vender R JDD Transitioning Between Brodalumab and Secukinumab in Moderate to Severe Psoriasis: An Early Look August 2016 Vol 15(8) pp941-43)
19. Georgakopoulos JR Phung M, Ighani, A, et al., Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies JAAD July 2018 79(1) pp 155-57
20. Gasslitter, I Kirsten, N., Augustin, M. et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.Arch Dermatol Res (2019).
21. Langley, R. , Tsai, T. , Flavin, S. , et.al. (2018), Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial. Br J Dermatol, 178: 114-123.
22. Clinical Response Following Re-Treatment with a Selective IL-23p19 Inhibitor Risankizumab (BI 655066) or Switching from Ustekinumab to Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis;Papp K, et al. (FC03.04; Oral Session; Thursday, September 29, 2016; 1:45-1:55 p.m. CET).
23. Hu, Y., Chen, Z., Gong, Y. et al. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis Clin Drug Investig (2018) 38: 191.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.
Ronald Vender MD FRCPC, Associate Clinical Professor of Medicine, Division of Dermatology, McMaster University, ON
Dr. Ron Vender is a Dermatologist who currently practices in Hamilton. He is the founder and director of Dermatrials Research Incorporated and Venderm Innovations in Psoriasis.? He has participated as principal investigator in over 100 clinical trials. He is Associate Clinical Professor at McMaster University in the Department of Medicine, Division of Dermatology. He is Honorary Staff at St. Joseph?s Healthcare in Hamilton ON. Dr. Vender serves on the editorial board of the Journal of Cutaneous Medicine and Surgery and reviewer for the JEADV, JAAD, and BJD. He is one of eight Canadians elected to the International Psoriasis Council, a member of the Canadian Professors of Dermatology and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. He represents Canada on several Global educational steering committees as well as international advisory boards. He has published many peer-reviewed manuscripts and has had posters, abstracts and lectures presented internationally.